4
H index
1
i10 index
34
Citations
Martina Garau : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 1 Articles 25 Papers 1 Books RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
14 years (2006 - 2020). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau. | Is cited by:
| Cites to:
|
Main data
Where Martina Garau has published?
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Consulting Reports / Office of Health Economics | 13 |
| Research Papers / Office of Health Economics | 7 |
| Briefings / Office of Health Economics | 4 |
Recent works citing Martina Garau (2020 and 2019)
| Year | Title of citing document |
|---|---|
| 2019 | Competition between on-patent medicines in Europe. (2019). Wilsdon, Tim ; Roediger, Alexander ; Azais, Boris ; Pendleton, Kathy ; Haderi, Artes. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:7:p:652-660. Full description at Econpapers || Download paper |
| 2020 | A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. (2020). Mott, David ; Hopkins, Michael M ; Mestre-Ferrandiz, Jorge ; Llewelyn, Martin J ; Hampson, Grace. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00516-0. Full description at Econpapers || Download paper |
| 2020 | Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. (2020). Molina-Lopez, T ; Montibeller, G ; Linch, M ; Angelis, A ; Kanavos, P ; Espin, J ; Arickx, F ; Orzel, K ; Zawada, A. In: Social Science & Medicine. RePEc:eee:socmed:v:246:y:2020:i:c:s0277953619305908. Full description at Econpapers || Download paper |
| 2019 | Fair prices for medicines? Exploring competent authorities’ and public payers’ preferences on pharmaceutical policies. (2019). Vogler, Sabine . In: Empirica. RePEc:kap:empiri:v:46:y:2019:i:3:d:10.1007_s10663-019-09446-5. Full description at Econpapers || Download paper |
| 2020 | Price Models for Multi-indication Drugs: A Systematic Review. (2020). Trapero-Bertran, Marta ; Segu-Tolsa, Jose Luis ; Puig-Junoy, Jaume ; Campillo-Artero, Carlos. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00517-z. Full description at Econpapers || Download paper |
| 2020 | Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. (2020). Pertile, Paolo ; LEVAGGI, ROSELLA. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:3:d:10.1007_s40258-019-00541-z. Full description at Econpapers || Download paper |
Works by Martina Garau:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2009 | Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefings. [Full Text][Citation analysis] | paper | 5 |
| 2007 | Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefings. [Full Text][Citation analysis] | paper | 2 |
| 2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefings. [Full Text][Citation analysis] | paper | 0 |
| 2011 | Exploring the Interdependency between Public and Charitable Medical Research In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2010 | Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2009 | Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2006 | Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2014 | Obstructive Sleep Apnoea: Health Economics Report In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2016 | Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2017 | Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
| 2018 | Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2019 | Unrelieved Pain in Palliative Care in England In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2020 | Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making? In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2020 | International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
| 2007 | European Medicines Pricing and Reimbursement: Now and the Future In: Monographs. [Full Text][Citation analysis] | book | 0 |
| 2011 | Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers. [Full Text][Citation analysis] | paper | 2 |
| 2013 | Exploring the link between health and wealth in decision making In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2013 | Multi-Criteria Decision Analysis to Value Orphan Medicines In: Research Papers. [Full Text][Citation analysis] | paper | 10 |
| 2012 | Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers. [Full Text][Citation analysis] | paper | 4 |
| 2010 | Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers. [Full Text][Citation analysis] | paper | 8 |
| 2014 | Exploring the Interdependencies of Research Funders in the UK In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
| 2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
| 2018 | R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated October, 6 2020. Contact: CitEc Team